scholarly journals Metabolic Abnormalities, Cardiovascular Disease Risk Factors, and GFR Decline in Children with Chronic Kidney Disease

2011 ◽  
Vol 6 (9) ◽  
pp. 2132-2140 ◽  
Author(s):  
Susan L. Furth ◽  
Alison G. Abraham ◽  
Judith Jerry-Fluker ◽  
George J. Schwartz ◽  
Mark Benfield ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Cardiovascular Disease Risk Factors ◽  
Metabolic Abnormalities ◽  
Gfr Decline

scholarly journals Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis

PLoS ONE ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. e0192895 ◽  
Author(s):  
Rupert W. Major ◽  
Mark R. I. Cheng ◽  
Robert A. Grant ◽  
Saran Shantikumar ◽  
Gang Xu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Risk ◽  
Meta Analysis ◽  
Cardiovascular Disease Risk ◽  
Cardiovascular Disease Risk Factors

scholarly journals Cardiovascular Disease Risk Factors in Chronic Kidney Disease

2006 ◽  
Vol 166 (17) ◽  
pp. 1884 ◽  
Author(s):  
Nisha I. Parikh ◽  
Shih-Jen Hwang ◽  
Martin G. Larson ◽  
James B. Meigs ◽  
Daniel Levy ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Cardiovascular Disease Risk Factors

scholarly journals Strategies for Controlling Blood Pressure and Reducing Cardiovascular Disease Risk in Patients with Chronic Kidney Disease

2015 ◽  
Vol 25 (4) ◽  
pp. 515 ◽  
Author(s):  
Keith C. Norris ◽  
Susanne B Nicholas
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Risk ◽  
Enzyme Inhibitor ◽  
Angiotensin Receptor Blockers ◽  
Cardiovascular Disease Risk ◽  
High Rate ◽  
Ckd Stage

<p>Patients with chronic kidney disease (CKD) suffer from an increased prevalence of cardiovascular disease (CVD) risk factors, and a high rate of premature CV morbidity and mortality. The confluence of CV risk factors, in the context of cardio-metabolic perturbations that vary as renal function declines, complicates strategies for the care of patients with CKD. Understanding the ex­isting evidence for effective CVD treatment strategies can help providers better care for these patients, navigate the complex treat­ment guidelines, which often differ across major organizations, and minimize the con­flicting recommendations that new studies may pose. A pragmatic approach is to target a BP &lt;140/90 mm Hg, which frequently requires more than two or three antihyper­tensive agents. Most guidelines recommend a combination of diuretic and angiotensin converting enzyme inhibitor or angiotensin receptor blockers, along with a dihydropyri­dine calcium channel blocker, beta blocker or other agent based on co-existing medical conditions. Consideration for a lower BP goal and/or other therapeutic interventions should be based on the etiology of CKD, stage of CKD, and/or presence of protein­uria. Finally, most patients with CKD, not on dialysis, would benefit from treatment with statins and non-pharmacologic lifestyle interventions should be promoted for all pa­tients with CKD. <em>Ethn Dis. </em>2015;25(4):515- 520; doi:10.18865/ed.25.4.515</p>

Sign in / Sign up

Export Citation Format

Share Document